NASDAQ:WHWK Whitehawk Therapeutics Q2 2026 Earnings Results & Report $3.02 -0.36 (-10.65%) Closing price 04:00 PM EasternExtended Trading$3.02 0.00 (0.00%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Whitehawk Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.20 versus the -$0.30 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market Opens Whitehawk Therapeutics EPS ResultsActual EPS-$0.20Consensus EPS -$0.30Beat/MissBeat by +$0.10One Year Ago EPSN/AEPS Beat Rate4 of last 5 quartersWhitehawk Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Whitehawk Therapeutics Q2 2026 Earnings FAQ Did Whitehawk Therapeutics beat earnings estimates for Q2 2026? Whitehawk Therapeutics (NASDAQ:WHWK) reported earnings of -$0.20 per share for Q2 2026, beating the consensus estimate of -$0.30. The report was announced on Thursday, August 6, 2026. Whitehawk Therapeutics Earnings HeadlinesWhitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 As A Durable ADC Target In Ovarian Cancer And Reinforces Scientific Rationale For HWK-016October 3, 2026 | marketscreener.comMWhitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026October 1, 2026 | prnewswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 13 at 1:00 AM | Investors Alley (Ad)Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comWhitehawk Therapeutics: PTK7 Stability Supports ADC Development In EGFR Wild-Type NSCLCSeptember 14, 2026 | rttnews.comWhitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026September 13, 2026 | prnewswire.comSee More Whitehawk Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Whitehawk Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Whitehawk Therapeutics and other key companies, straight to your email. Email Address About Whitehawk TherapeuticsWhitehawk Therapeutics (NASDAQ:WHWK) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s work centers on precision medicines intended to selectively target diseased cells while limiting damage to healthy tissue. Whitehawk Therapeutics is advancing a pipeline of investigational therapeutic programs, with development activities focused primarily on oncology. As a clinical-stage company, its product candidates remain subject to preclinical and clinical testing, as well as review by applicable regulatory authorities, before any potential commercialization. Publicly available information about the company’s specific pipeline, geographic operations, and leadership is limited. Whitehawk Therapeutics is headquartered in the United States and is listed on the Nasdaq under the symbol WHWK.View Whitehawk Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
